RTW Biotech Opportunities – executive interview

RTW Biotech Opportunities – executive interview

RTW Biotech Opportunities — 1 video in collection

More on this equity

Edison’s head of investment companies, Rob Murphy, met Roderick Wong, managing director of RTW Investments, to discuss RTW Biotech Opportunities (RTW Bio; ticker RTW/RTWG). Wong outlines RTW Bio’s outperformance versus its two biotech index benchmarks in 2023 and since the fund’s launch in October 2019. He also discusses his outlook for the biotech industry in 2024. Furthermore, Wong highlights RTW Bio’s acquisition of Arix Bioscience’s assets and the anticipated timeline for the deal to be completed. Finally, Wong reiterates his vision for RTW Bio and how it fits in with RTW Investments’ other funds.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free